Dr. Jalaja Potluri, Executive Medical Director at AbbVie and the Development Leader for VENCLEXTA (venetoclax) discusses data on VENCLEXTA reinforcing the efficacy and versatility of this treatment in numerous blood cancers, including acute myeloid leukemia (AML)(abstract 1271), myelodysplastic syndrome (MDS)(abstract 537), and chronic lymphocytic leukemia (CLL). These data were presented at the 2021 American Society of Hematology (ASH) Annual Meeting. Visit www.hematology.org to learn more.
Dr. Jalaja Potluri is an Executive Medical Director at AbbVie and the Development Leader for VENCLEXTA (venetoclax). Dr. Potluri is a hematologist and medical oncologist focused on developing transformational treatments for patients with blood cancers. She has developed and conducted several studies that led to VENCLEXTA’s FDA approvals in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Prior to joining the VENCLEXTA clinical development team in 2013, Dr. Potluri was a faculty member at the University of Illinois and at the Advocate Health Centers, where she had been involved in national co-operative oncology trials in blood cancers and was the director of the cancer committee. Dr. Potluri completed her M.D. at Nagarjuna University in India, and fellowship training in Hematology and Medical Oncology at the Medical College of Wisconsin.